Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

549 results about "Early rheumatoid arthritis" patented technology

Persistent stiffness, tenderness, and pain in joints may be an early sign of rheumatoid arthritis. Another early sign of RA is joint stiffness. Stiffness may occur in one or two small joints, often in the fingers.

Application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof

The invention provides application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides dorei. Applied to animals, the bacteroides dorei can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides dorei can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.
Owner:BGI SHENZHEN CO LTD +1

Application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof

The invention provides an application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof, and also provides bacteroides caccae containing pharmaceutical compositions, medicaments, foods and feeds. By providing bacteroides caccae for animals, an anti-inflammatory effect can be effectively played, the symptoms such as redness and swelling of joints are effectively improved, and the symptoms of arthritis are obviously relieved, and therefore, the bacteroides caccae can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.
Owner:BGI SHENZHEN CO LTD +1

Blaster for treating rheumatoid arthritis

A Chinese medicine in the form of plaster for treating rheumatic arthritis, cervical spondylopathy, lumbar intervertebral disk protrusion, lumbar hyperosteogeny, etc is prepared from the Chinese-medicinal materials. Its advantages are simple preparing process, high curative effect, and short course of treatment.
Owner:吴立让

Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis. This invention also provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate for use in treating a subject afflicted with rheumatoid arthritis.
Owner:TEVA PHARMA IND LTD

Heated garment for medical applications

A patient-treatment system and related method provide relief from, and treatment for, muscle spasticity disorders, Willis-Ekbom disease, contracture, sleep onset insomnia, sleep maintenance insomnia, rheumatoid arthritis, and other similar disorders by applying controlled heat, and optionally muscle monitoring / stimulation, to one or more parts of a patient's body.
Owner:BIRCH TREE MEDICAL

Methods of treating rheumatoid arthritis using il-17 antagonists

ActiveUS20130209480A1Inhibitory activityRapid improvement of clinical manifestationOrganic active ingredientsAntipyreticSecukinumabAntigen
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Owner:NOVARTIS AG

Macrolide derivatives

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).
Owner:TAISHO PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products